CHMP recommends marketing authorization of Cosentyx (secukinumab) in adolescents aged 12+ with hidradenitis suppurativa – Novartis
Novartis announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending marketing authorization of Cosentyx (secukinumab) for adolescents aged 12 years and older with active moderate to severe hidradenitis suppurativa who have had an inadequate response to conventional systemic HS therapy.
If approved by the European Commission (EC), Cosentyx would become the only interleukin-17A (IL-17A) inhibitor approved for adolescent HS in Europe and the first innovative biologic treatment option for this population in nearly a decade, addressing a significant unmet need where treatment options remain limited.
HS is a chronic, systemic, progressive and often painful inflammatory skin disease. It causes recurring boil-like abscesses that can burst, creating open wounds, often in the most intimate parts of the body, which may result in irreversible scarring. More than 50% of cases begin during puberty.
“Hidradenitis suppurativa often begins during adolescence, a critical period when the disease can progress to irreversible scarring, yet we currently have limited treatment options for this age group,” said Dr. John Ingram, Clinical Professor, Cardiff University School of Medicine, United Kingdom. “This positive CHMP opinion for secukinumab represents an important step toward addressing a meaningful gap in care for young people living with this challenging disease.”
The CHMP positive opinion is based on evidence demonstrating that weight-based dosing in adolescents aged 12 years and older provides Cosentyx exposure generally comparable to that observed in adults with HS. This includes efficacy and safety data from adult HS clinical studies, pharmacokinetic modeling extrapolated from adult HS and psoriasis clinical trials, pediatric clinical trial data from other approved Cosentyx indications, and weight-based dosing analyses. The safety profile of Cosentyx is well-established across several approved adult and pediatric indications.
“For over a decade, Cosentyx has helped transform outcomes across several immune-mediated diseases, including hidradenitis suppurativa. Adolescents living with moderate to severe HS deserve access to more advanced treatment options,” said Patrick Horber, President, International, Novartis. “This positive CHMP opinion brings us closer to that goal in Europe, and we look forward to the European Commission decision in the coming months.”
The EC is expected to issue a final decision within approximately two months, following today’s (13/11/2026) CHMP opinion.




